Approximately 100,000 men are diagnosed with Grade Group 1 (GG1) prostate cancer annually in the United States. This figure represents the earliest and lowest-risk form of the disease, which accounts for a significant portion of the 333,830 total new prostate cancer cases projected for 2026.
While GG1 cases are numerous, recent trends show a shift in diagnosis and management:
- The proportion of localized prostate cancers classified as low risk has declined from roughly 28.8% to 24.0% in recent registry data.
- Consequently, the proportion of patients treated with radiation for low-risk disease has dropped significantly, with many now managed through active surveillance rather than immediate treatment.
“…the majority of impalpable prostate carcinomas are low volume, well differentiated tumours corresponding to clinically insignificant neoplasms…”
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force, 2008
“The absolute mortality risk reduction with screening, however, was less than 1 per 1,000 men, implying that more than 1,400 men needed to be screened to prevent 1 prostate cancer death in 9 years of follow-up.” (re: PLCO, ERSPC trials)
Reconciling Primary Care and Specialist Perspectives on Prostate Cancer Screening
Ann Fam Med. 2012; 10(6):568-571
“Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate cancer mortality, as compared with observation, through at least 12 years of follow-up. Absolute differences were less than 3 percentage points.”
Radical Prostatectomy versus Observation for Localized Prostate Cancer, 2012
Ask AI:
How many prostate cancer deaths per year in U.S.?
In the United States, there are approximately 36,320 prostate cancer deaths projected per year in 2026.{1,2,3,4] Recent recorded data indicates a “decline-then-rebound” trend, with 34,815 deaths reported in 2024 and 33,860 in 2023.
The death rate was 18.9 per 100,000 men per year based on 2020–2024 data.[2] While mortality rates declined by about half from 1993 to 2022 due to earlier detection and treatment advances, the absolute number of deaths has stabilized or slightly increased in recent years, largely reflecting the effects of an aging population.[4]
AI-generated answer. Please verify critical facts.
References
[1] Prostate Cancer Statistics 2026
Cancer Therapy Advisor, 2026
https://www.cancertherapyadvisor.com/factsheets/prostate-cancer-statistics/
[2] Cancer Stat Facts: Prostate Cancer
SEER, NCI, 2026
https://seer.cancer.gov/statfacts/html/prost.html
\Prostate Cancer — Cancer Stat Facts 2026.pdf
[3] Key Statistics for Prostate Cancer
Cancer, ACS, 2026
https://www.cancer.org/cancer/types/prostate-cancer/key-statistics.html
\statistic prostate cancer ACS 2026
[4] Prostate Cancer
Johns Hopkins, 2026
https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer
\Prostate Cancer _ Johns Hopkins Medicine 2026.pdf
How many prostatectomies performed in U.S. each year?
Approximately 90,000 prostatectomy procedures are performed in the United States each year.
Specific data points indicate:
- 2022 Volume: A market research report recorded 82,728 procedures in 2022.
- Surgical Approach: Of the radical prostatectomies performed, an estimated 70,000 (roughly 70-95% depending on the year) are conducted using robotic-assisted techniques.
- Surgeon Volume: Despite the high national total, the majority of urologists perform low annual volumes; 60% of surgeons perform fewer than 5 prostatectomies per year, and only 20% perform 15 or more annually.
How many prostate IMRTs performed in U.S. each year?
The provided search context does not contain specific annual volume data for IMRT (Intensity-Modulated Radiation Therapy) procedures performed in the U.S.
The context does provide related statistics on radiation therapy utilization and prostate cancer diagnoses:
- Approximately 175,000 men are newly diagnosed with prostate cancer in the U.S. each year.
- In a 2006–2008 study, 87% of newly diagnosed patients received external beam radiation therapy, with IMRT accounting for 62–74% of those treatments.
- National trends indicate a significant shift toward IMRT, which rose from 29% of external beam radiation in 2002 to 82% by 2005.
To determine the exact number of annual IMRTs, one would need to apply these historical percentages to current annual diagnosis and treatment volumes, but precise current IMRT procedure counts are not available in the provided text.
“At peak US screening rates (~300,000+ annual diagnoses), with 20–50% overdiagnosis and ~90% treatment uptake, the number of men undergoing unnecessary treatment was on the order of tens of thousands per year.”
AI ‘Conversation’
1. USPSTF moratorium psa screening long-term effects?
The 2012 USPSTF Grade D recommendation against routine PSA screening, which effectively created a de facto moratorium, led to an immediate 10–12% drop in screening rates and a 28% decrease in new prostate cancer diagnoses within a year. [1]
Long-term consequences observed in subsequent studies include:
- Increased Metastatic Disease: While overdiagnosis of low-risk cancer decreased, there was a concomitant rise in the detection of unfavorable-risk and metastatic disease, particularly in men aged 50–74.[1] (2018 study citing percentage of a very small number cases)
- Stagnant Mortality Rates: Prostate cancer-specific mortality (PCSM) rates, which had been declining prior to 2012, stagnated following the recommendation, suggesting a potential loss of mortality benefit.
- Policy Revision: Due to these long-term effects and the increased use of active surveillance to mitigate harms, the USPSTF revised its guidelines in 2018 to a Grade C recommendation for men aged 55–69, emphasizing shared decision-making rather than universal discouragement.[2,3,4]
References
[1]Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening
American Cancer Society, Dec 3, 2019
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32605
\Long‐term consequences of the USPSTF Grade D recommendation for prostate‐specific antigen screening – ACS Dec 2019.pdf
[2] Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases
Weill Cornell Medicine, Apr 22, 2022
\Less Prostate Cancer Screening Reduces Overdiagnosis but May Miss Aggressive Cases _ Newsroom _ Weill Cornell Medicine Apr 2022.pdf
[3] Screening for Prostate CancerUS Preventive Services Task Force Recommendation Statement
USPSTF, JAMA Network, May 8, 2018
\Screening Prostate Cancer recommendations USPSTF 2018.pdf
[4] PSA Screening: Shared Decision-Making Is a Flawed Approach
American Family Physician, Jan 2025
https://www.aafp.org/afp/2025/0100/editorial-psa-screening
\PSA Screening_ Shared Decision-Making Is a Flawed Approach _ AFP 2025.pdf
2. Regarding the referenced “rise in unfavorable-risk and metastatic disease,” can you provide the actual numbers or cases in each category and provide researchers’ definition of “unfavorable risk?”
Retrieved prostate cancer risk definitions
Here are the specific numbers from the major studies, followed by how “unfavorable” was defined.
| Study | Metric | Before 2012 | After 2012 | Change |
| Nguyen et al. (AUA 2022) | Odds of Gleason Grade 4–5 (pGS4/5) at prostatectomy | Reference | 3.2× higher (p < 0.001) | — |
| Nguyen et al. (AUA 2022) | Odds of pT3a (extracapsular extension) | Reference | 2.4× higher (p < 0.001) | — |
| Nguyen et al. (AUA 2022) | Lymph node metastasis | Reference | OR 1.31 (95% CI 1.23–1.39) | — |
| Nguyen et al. (AUA 2022) | Metastatic disease at diagnosis | Reference | RRR 1.23 (95% CI 1.16–1.30) | — |
| Medscape-reported study (2018) | High-grade GS 8+ cancers | 6.2% of diagnoses | 17.5% of diagnoses | +24% absolute |
| Medscape-reported study (2018) | Low-grade GS 3+3 cancers | 30.2% | 17.1% | −13.1 pts |
| Medscape-reported study (2018) | PSA > 20 ng/mL | 2.4% | 4.2% | +44% |
| Chou et al. (JAMA Netw Open 2020) | Metastatic (stage IV) cancers | Reference | +36.9% (95% CI 9.5–71.0), i.e., 75 more stage IV cases | — |
| Chou et al. (JAMA Netw Open 2020) | Incident cancers overall | Reference | −53.5% (1,871 fewer) | — |
| Jemal et al. (CA Cancer J Clin 2017) | Age-std. metastatic PCA incidence trend | −1.45%/yr (2004–07) | +2.74%/yr from 2012 onward | — |
| JAMA Netw Open (2022), ages 45–74 | Distant mPCa rate | 9.66/100k (2004) → 10.7/100k (2012) | +41% by 2018 | — |
| JAMA Netw Open (2022), ages 75+ | Distant mPCa rate | 143.94/100k (2004) → 96.92/100k (2012) | +43% from 2011–2018 | — |
| 2026 interrupted time-series study | Metastatic disease | Reference | +9.3% immediately post-2012 | — |
| 2026 interrupted time-series study | Overall incidence | Reference | −20.6% immediately post-2012 | — |
Chou et al. summarized the trade-off: “For every 25 fewer cancers detected, one metastatic cancer was diagnosed.” [1]
Definition of “Unfavorable”
The term is used at two distinct levels in the literature:
Pathologic “unfavorable” (as in the Nguyen et al.[2] prostatectomy studies): A composite of adverse features at radical prostatectomy, specifically:
- Gleason Grade Group 4 or 5 (Gleason score 8, 9, or 10) — i.e., any Gleason pattern 4 (majority) or pattern 5 component
- pT3a (extracapsular extension) or pT3b (seminal vesicle invasion)
- Some studies also include pN1 (positive lymph nodes) and positive surgical margins[3,4,5]
A 2014 study defined it more simply: “Pathologically unfavorable PCa was defined as tumors that were non-organ-confined or having Gleason pattern 4 or 5 tumor foci.” [6]
Clinical “high-risk” (NCCN/EAU standard, used in the metastatic incidence studies): Any one of:
- PSA > 20 ng/mL
- Gleason score 8–10 (Grade Group 4 or 5)
- Clinical stage T3–T4 (tumor extending beyond the prostate capsule or invading seminal vesicles/adjacent structures) [7,8]
“Very high risk” (a subset): cT3b–T4, primary Gleason pattern 5, or ≥ 2 high-risk features simultaneously.[8,9,10]
The 2024 Nguyen histopathology paper proposed a more granular “unfavorable histology” definition independent of grade group: any classic Gleason pattern 5, large cribriform morphology (>0.25 mm), intraductal carcinoma, complex papillary architecture, grade 3 stromogenic carcinoma, or complex anastomosing cord-like growth — but this is a research proposal, not yet standard clinical terminology. [2]
References
[1] Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice
Journal of General Internal Medicine, Dec 19, 2019
https://link.springer.com/article/10.1007/s11606-019-05561-y
\Changes in Prostate Cancer presentation post USPSTF 2012 stmt 2019,pdf
[2] Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage
Histopathology, Jun 3, 2024
https://onlinelibrary.wiley.com/doi/10.1111/his.15231
\Proposal for an optimised definition of adverse pathology – Histopathology 2024.pdf
Unfavourable histology at radical prostatectomy is associated with metastatic risk, predicted adverse outcomes better than current grading and staging systems and improved the MSKCC post-prostatectomy nomogram. Most importantly, unfavourable histology stratified grade group 2 prostate cancers into those with and without metastatic potential, independent of stage. While unfavourable histology is driven predominantly by large cribriform/intraductal carcinoma, the recognition and inclusion of other specific architectural patterns add to the sensitivity for predicting metastatic disease.
[3] https://www.medicinenet.com/prostate_cancer/article.htm
[5] https://www.cancerresearchuk.org/about-cancer/prostate-cancer/stages/cambridge-prognostic-group-cpg
[6] https://pmc.ncbi.nlm.nih.gov/articles/PMC4558555/
[8] https://www.medicinenet.com/prostate_cancer/article.htm
[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC5559730/
[10] https://www.sciencedirect.com/science/article/abs/pii/S036030161933398X
3. Results provide only percentage change for every category. Since fewer screenings can typically lead to increased percentage of higher-risk cancers detected, can you provide the actual numbers of cases per study?
Retrieving raw case counts from studies
You raise a valid methodological point. When the denominator (total cancers detected) shrinks, the proportion of high-grade/metastatic cases rises mechanically even if absolute counts are flat. Here’s what actual case numbers are available from each study:
Nguyen et al. (Weill Cornell, 2022) — NCD, radical prostatectomy
| Metric | Pre (2004–2011, n=262,649) | Post (2013–2020, n=297,381) |
| Metastatic at diagnosis | 3.0% → ~7,879 cases | 5.2% → ~15,464 cases |
| Gleason Grade Group 1 on pathology | 32% → ~84,047 cases | 10% → ~29,738 cases |
Net: roughly 7,585 more metastatic cases and ~54,309 fewer low-grade (GG1) cases over 8 years each. However, the post cohort is ~13% larger in absolute size, so part of the metastatic increase reflects population growth rather than a pure rate effect.
Chou et al. (JAMA Netw Open, 2020) — Kaiser Permanente
This is the study that reported the most concrete absolute number:
- 1,871 fewer incident prostate cancers detected overall
- 75 more stage IV (metastatic) cancers diagnosed
- Their ratio: “For every 25 fewer cancers detected, one metastatic cancer was diagnosed.”
Chou et al. (JAMA Netw Open, 2022) — SEER 2004–2018
| Group | Total distant mPCa cases (15 yr) | Rate 2004 | Rate 2012 | Post-2012 trend |
| Men 45–74 | 26,642 | 9.66/100k | 10.7/100k | +41% by 2018 |
| Men 75+ | 20,507 | 143.94/100k | 96.92/100k | +43% from 2011–2018 |
The study does not break out per-year absolute counts in the abstract, but the total of 47,149 distant mPCa cases over 15 years (~3,143/yr average) gives a baseline against which the +41–43% rate increases can be contextualized. [1]
VHA Study (JAMA Oncol, 2022) — cleanest per-year absolute counts
| Year | Metastatic PCa cases | Nonmetastatic PCa (IR/100k) | Metastatic PCa (IR/100k) |
| 2012 | 1,039 | 79.8 | 5.4 |
| 2013 | 1,087 | 75.1 | 5.6 |
This shows a modest absolute increase (~48 more cases in one year) alongside a ~6% drop in nonmetastatic incidence.
Kaiser Permanente (PMC 7210336, 2019) — per-year N
| Year | Total PCa (N) | Stage IV (N) |
| 2010 | 2,063 | 57 |
| 2011 | 1,968 | 69 |
| 2012 | 1,840 | 53 |
| 2013 | 1,710 | 68 |
Here the stage IV count is actually noisy (53 in 2012, 68 in 2013) and doesn’t show a dramatic absolute jump year-over-year — consistent with the user’s concern that proportion shifts can overstate the effect.
You’re correct that most of the headline statistics (OR 1.31, RRR 1.23, “36.9% increase”) are relative measures computed on a shrinking denominator. The studies that report the strongest absolute signal are:
- Chou 2020: +75 metastatic cases (small absolute number, large relative effect)
- Nguyen 2022: ~7,500 additional metastatic cases over 8 years (but confounded by cohort size growth)
- SEER 2022: +41–43% rate increase in distant mPCa (absolute per-year counts not published in the abstract)
The Butler et al. (Cancer, 2020) NCCN risk-group analysis similarly reports only incidence rates per 100,000 (6.2→7.1 for ages 50–74; 16.8→22.6 for ≥75), not raw case counts.
Bottom line: The absolute increase in metastatic cases is real but modest in scale (hundreds to low thousands per year nationally), while the absolute decrease in low-grade overdiagnosed cases is far larger (tens of thousands). The proportion-based framing amplifies the harm signal relative to the benefit signal.
Reference
[1] Trends in Incidence of Metastatic Prostate Cancer in the US
JAMA Network, Urology, Mar 14, 2022
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790041
https://dx.doi.org/10.1001/jamanetworkopen.2022.2246
4. The Task Force’s recommendations explicitly noted alarming volume of overtreatment of insignificant, non-life-threatening cancers. The argument for increase in advanced cancers detected, in real numbers, represents an extremely small cohort in comparison.
Retrieved USPSTF overtreatment statistics
Correct. The asymmetry is stark when stated in absolute terms:
The Harm Being Prevented (Overtreatment)
The USPSTF’s 2012 recommendation was built on these figures:
- Overdiagnosis: 21% of screen-detected cancers (PLCO) to 50% (ERSPC) would never have become symptomatic in the man’s lifetime
- Treatment uptake: ~90% of men with localized PCa underwent prostatectomy or radiation
- The ratio the Task Force cited: 48 men were treated for every 1 prostate cancer death prevented (ERSPC)
- Treatment harms (NEJM 2013, 15-year follow-up):
- Erectile dysfunction: 87% (prostatectomy), 94% (radiation)
- Urinary incontinence: 18.3% (RP), 9.4% (RT) at 15 years
- A 2024 follow-up found 61% of surgically treated men and 42% of RT-treated men experienced ≥1 treatment-related complication by 12 years, vs. 24% of untreated men [1]
At peak US screening rates (~300,000+ annual diagnoses), with 20–50% overdiagnosis and ~90% treatment uptake, the number of men undergoing unnecessary treatment was on the order of tens of thousands per year.
The Potential Harm (Missed/Metastatic Cancers)
From the studies already discussed:
- Chou 2020 (Kaiser): 75 additional stage IV cases
- VHA 2022: ~48 additional metastatic cases in one year
- SEER 2022: +41–43% rate increase on a national base of ~3,100 distant mPCa cases/year → roughly ~1,000–1,300 additional cases at the national peak
| Scale (per year, US) | |
| Men avoiding unnecessary treatment | ~20,000–50,000+ |
| Additional metastatic diagnoses | ~500–1,300 |
The ratio is roughly 15:1 to 50:1 in favor of the overtreatment reduction. Even taking the most pessimistic metastatic estimates and the most conservative overdiagnosis estimates, the absolute number of men spared from incontinence, erectile dysfunction, and bowel complications dwarfs the number of men who may have presented with more advanced disease.
This is precisely the calculus the 2012 Grade D recommendation was making — and it’s why the 2018 revision to Grade C (shared decision-making) was a compromise rather than a full reversal: the Task Force acknowledged the small absolute metastatic risk while maintaining that the net benefit of universal screening was not positive.
References
[1] Screening for Prostate CancerUS Preventive Services Task Force Recommendation Statement
JAMA Network, USPSTF, May 8, 2018
https://jamanetwork.com/journals/jama/fullarticle/2680553
\Screening Prostate Cancer recommendations USPSTF 2018.pdf
Prostate Cancer: Screening
U.S. Preventive Services Task Force, May 12, 2012
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening-2012
Current recommendation:
Prostate Cancer: Screening (2018)
How Did the USPSTF Arrive at This Recommendation? (May 11, 2012)
Evidence Summary (October 07, 2011)
Final Evidence Review: Screening for Prostate Cancer (October 15, 2011)
Final Evidence Review: Treatments for Localized Prostate Cancer (October 15, 2011)